Washington, DCA recent report from The New York Times (2/21/12) indicates that DePuy Orthopaedics knew well before its hip implant recall was announced that its all-metal devices were failing prematurely. Certain DePuy devices were recalled in 2010 following reports of high hip replacement failure. As The New York Times report shows, however, not only was DePuy likely aware of problems with hip implant failure, the FDA had rejected one of the company's recalled devices because of the high failure rate.
The New York Times article cites an internal e-mail written in August 2009, from a DePuy executive regarding its all-metal ASR Hip Resurfacing System. The e-mail informs others that the US Food and Drug Administration (FDA) rejected one of the DePuy hip replacement devices because of a high failure rate. According to the e-mail, the FDA refused the device because the company's own studies showed a high premature failure rate in patients.
The device in question, the DePuy ASR Hip Resurfacing System, was sold overseas, while a similar device—the DePuy ASR XL Acetabular—was used in the US. Both devices are all-metal hip replacement systems—based on the use of an all-metal hip socket—and have been linked to an increased risk of premature failure. Furthermore, as with other all-metal hip devices, the DePuy hip replacements have been linked to an increased risk of metallosis, a condition in which metal debris comes loose from the device and is absorbed by the patient's surrounding tissue.
The DePuy e-mail seemingly contradicts assertions from DePuy executives that the company was not aware of the high failure rates prior to the recall and, furthermore, that the company's own studies showed that the all-metal hip replacement implants were safe. Initially, when reports came in about the DePuy premature failures, the company blamed the issue on surgeons rather than the device.
But according to the e-mail from the DePuy executive, "There have been a significant number of revisions [surgeries to replace a failed hip implant device] within the ASR group as opposed to very few in the control group," (as published by The New York Times, 2/21/12).
What effect news of the FDA's rejection of the DePuy device will have on the lawsuits filed against the company remains to be seen. Approximately 93,000 patients in the US and overseas received one of the devices. It is not illegal for DePuy to keep the non-approval letter private, nor is it illegal to market products overseas that were rejected by the FDA.
Lawsuits have been filed against DePuy and Johnson & Johnson, alleging their DePuy hip replacement devices had unreasonably high premature failure rates. In 2009, DePuy Orthopaedics announced that it was phasing out the ASR implant due to business reasons. A recall of the ASR systems was announced in 2010.
If you or a loved one have suffered losses in this case, please click the link below and your complaint will be sent to a defective products lawyer who may evaluate your Hip and Knee Replacement claim at no cost or obligation.